


JC17 Rec'd PCT/PTO 20 SEP 2005

b.) Amendment to the Claims:

1. (Original) An antitussive which comprises, as an active ingredient, a tricyclic compound represented by Formula (I)



{wherein R¹ represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy or halogen,


X¹-X²-X³ represents CR⁵=CR⁶-CR⁷=CR⁸ [wherein R⁵, R⁶, R⁷ and R⁸ may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, hydroxy, substituted or unsubstituted lower alkoxy, nitro, amino, mono(lower alkyl)-substituted amino, di(lower alkyl)-substituted amino, substituted or unsubstituted lower alkanoylamino or halogen], N(O)_m=CR⁶-CR⁷=CR⁸ (wherein R⁶, R⁷ and R⁸ have the same meanings as defined above, respectively and m represents 0 or 1), CR⁵=CR⁶-N(O)_m=CR⁸ (wherein R⁵, R⁶, R⁸ and m have the same meanings as defined above, respectively), CR⁵=CR⁶-CR⁷=N(O)_m (wherein R⁵, R⁶, R⁷ and m have the same meanings as defined above, respectively), CR⁵=CR⁶-O (wherein R⁵ and R⁶ have the same meanings as defined above, respectively), CR⁵=CR⁶-S (wherein R⁵ and R⁶ have the same meanings as defined above, respectively), O-CR⁷=CR⁸ (wherein R⁷ and R⁸ have the same meanings

as defined above, respectively), $S-CR^7=CR^8$ (wherein R^7 and R^8 have the same meanings as defined above, respectively) or $O-CR^7=N$ (wherein R^7 has the same meaning as defined above),

Y represents $-CH_2S-$, $-CH_2SO-$, $-CH_2SO_2-$, $-CH_2O-$, $-CH=CH-$, $-(CH_2)_p-$ (wherein p represents an integer of 0 to 2), $-SCH_2-$, $-SOCH_2-$, $-SO_2CH_2-$ or $-OCH_2-$, and

R^2 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkoxy, amino, mono(substituted or unsubstituted lower alkyl)-substituted amino, di(substituted or unsubstituted lower alkyl)-substituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkylamino, substituted or unsubstituted arylamino, or a substituted or unsubstituted heterocyclic group} or a pharmaceutically acceptable salt thereof.

2. (Original) An antitussive which comprises, as an active ingredient, a tricyclic compound represented by Formula (Ia)



[wherein R¹ and X¹-X²-X³ have the same meanings as defined above,
respectively,


Y^a represents -CH₂SO₂-, -SCH₂-, -SOCH₂-, -SO₂CH₂- or -OCH₂- and

when Y^a is -CH₂SO₂-, -SCH₂-, -SOCH₂- or -SO₂CH₂-,

R^{2a} represents a hydrogen atom, substituted or unsubstituted lower alkyl,
substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkoxy,
amino, mono(substituted or unsubstituted lower alkyl)-substituted amino, di(substituted or
unsubstituted lower alkyl)-substituted amino, substituted or unsubstituted aryl, substituted
or unsubstituted heteroaryl, substituted or unsubstituted aralkylamino, substituted or
unsubstituted arylamino, a substituted or unsubstituted heteroalicyclic group, or a
substituted or unsubstituted nitrogen-containing heterocyclic group and

when Y^a is -OCH₂-,

R^{2a} represents a hydrogen atom, trifluoromethyl, substituted or
unsubstituted lower alkenyl, substituted or unsubstituted lower alkoxy, amino,
mono(substituted or unsubstituted lower alkyl)-substituted amino, di(substituted or
unsubstituted lower alkyl)-substituted amino, substituted or unsubstituted aryl, substituted
or unsubstituted heteroaryl, substituted or unsubstituted aralkylamino, substituted or
unsubstituted arylamino, a substituted or unsubstituted heteroalicyclic group, a substituted
or unsubstituted nitrogen-containing heterocyclic group, or Formula (II)



(II)

(wherein n is 0 or 1; R³ and R⁴ may be the same or different and represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl, or R³ and R⁴ may be combined together with the adjacent carbon atom thereto to form cycloalkyl; and Q represents hydroxy, substituted or unsubstituted lower alkoxy, amino or halogen)] or a pharmaceutically acceptable salt thereof.

3. (Original) The antitussive according to Claim 2, wherein Y^a is -CH₂SO₂-, -SCH₂-, -SOCH₂- or -SO₂CH₂-.

4. (Original) The antitussive according to Claim 2, wherein Y^a is -OCH₂-.

5. (Original) The antitussive according to any of Claims 2 to 4, wherein R¹ is a hydrogen atom, substituted or unsubstituted lower alkoxy or halogen.

6. (Original) The antitussive according to any of Claims 2 to 4, wherein R¹ is a hydrogen atom.

7. (Currently Amended) The antitussive according to ~~any of Claims 2, 5 and 6~~ claim 2, wherein Y^a is -CH₂SO₂-, -SO₂CH₂- or -OCH₂- and R¹ is a hydrogen atom, substituted or unsubstituted lower alkoxy or halogen.


8. (Currently Amended) The antitussive according to ~~any of Claims 2, 5 and 6~~ claim 2, wherein Y^a is -CH₂SO₂- or -SO₂CH₂- and R¹ is a hydrogen atom, substituted or unsubstituted lower alkoxy or halogen.

9. (Currently Amended) The antitussive according to ~~any of Claims 2, 5 and 6~~ claim 2, wherein Y^a is -CH₂SO₂- and R¹ is a hydrogen atom, substituted or unsubstituted lower alkoxy or halogen.

10. (Currently Amended) The antitussive according to any of ~~Claims 2 to 9~~ claims 2 to 4, wherein X¹-X²-X³ is S-CR⁷=CR⁸ (wherein R⁷ and R⁸ have the same meanings as defined above, respectively).

11. (Currently Amended) The antitussive according to any of ~~Claims 2 to 9~~
claims 2 to 4, wherein $X^1-X^2-X^3$ is $CR^5=CR^6-CR^7=CR^8$ (wherein R^5 , R^6 , R^7 and R^8 have
the same meanings as defined above, respectively).

12. (Currently Amended) The antitussive according to any of ~~Claims 2 to~~
claims 2 to 4, wherein R^{2a} is Formula (II)




(wherein n , R^3 , R^4 and Q have the same meanings as defined above,
respectively).

13. (Original) The antitussive according to Claim 12, wherein n is 0.


14. (Original) The antitussive according to Claim 13, wherein R^3 is
methyl, R^4 is trifluoromethyl, and Q is hydroxy.

15. (Original) The antitussive according to Claim 2, wherein R^1 is a hydrogen atom, Y^a is $-\text{CH}_2\text{SO}_2-$, $X^1-X^2-X^3$ is $\text{S}-\text{CR}^7=\text{CR}^8$ (wherein R^7 and R^8 have the same meanings as defined above, respectively), and R^2 is Formula (III)



(III)

16. (Original) An antitussive which comprises, as an active ingredient, a tricyclic compound represented by Formula (Ib)




(Ib)

[wherein R^1 and $X^1-X^2-X^3$ have the same meanings as defined above, respectively,

Y^b represents $-\text{CH}_2\text{O}-$, $-\text{CH}_2\text{S}-$, $-\text{CH}_2\text{SO}-$, $-\text{CH}=\text{CH}-$ or $-(\text{CH}_2)_p-$ (wherein p has the same meaning as defined above) and

R^{2b} represents Formula (III)



or a pharmaceutically acceptable salt thereof.

17. (Original) The antitussive according to Claim 16, wherein $X^1-X^2-X^3$ is $CR^5=CR^6-CR^7=CR^8$ (wherein R^5 , R^6 , R^7 and R^8 have the same meanings as defined above, respectively) or $CR^5=CR^6-CR^7=N$ (wherein R^5 , R^6 and R^7 have the same meanings as defined above, respectively).

18. (Original) The antitussive according to Claim 16, wherein $X^1-X^2-X^3$ is $CR^5=CR^6-O$ (wherein R^5 and R^6 have the same meanings as defined above, respectively) or $CR^5=CR^6-S$ (wherein R^5 and R^6 have the same meanings as defined above, respectively).

19. (Original) The antitussive according to Claim 16, wherein $X^1-X^2-X^3$ is $O-CR^7=CR^8$ (wherein R^7 and R^8 have the same meanings as defined above, respectively) or $S-CR^7=CR^8$ (wherein R^7 and R^8 have the same meanings as defined above, respectively).

20. (Original) The antitussive according to any of Claims 16 to 19,
wherein Y^b is $-\text{CH}_2\text{O}-$.

21. (Original) The antitussive according to any of Claims 16 to 19,
wherein Y^b is $-(\text{CH}_2)_p-$ (wherein p has the same meaning as defined above).

22. (Original) The antitussive according to Claim 21, wherein p is 0.

23. (Original) The antitussive according to Claim 21, wherein p is 2.

24. (Original) The antitussive according to any of Claims 16 to 19,
wherein Y^b is $-\text{CH}=\text{CH}-$.

25. (Original) The antitussive according to any of Claims 16 to 19,
wherein Y^b is $-\text{CH}_2\text{S}-$ or $-\text{CH}_2\text{SO}-$.

26. (Original) A method for alleviation of a cough, which comprises a step of administering an effective amount of the tricyclic compound or the pharmaceutically acceptable salt thereof described in any of ~~Claims 1 to 25~~ claims 1 to 4 or 16-19.

Claims 27 (Cancelled).